In bladder cancer patients’ samples, IL-1β is highly expressed and induces the urokinase-type plasminogen activator receptor and MMP9 expression by activating the MAPK and NF-κB pathways, thus promoting bladder cancer cell invasion [106,107]. Here, IL1B is linked to urinary bladder carcinoma.